Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.

The International Peripheral T-cell Lymphoma Project is a collaborative effort to better understand peripheral T-cell lymphoma (PTCL). A total of 22 institutions submitted clinical and pathologic material on 1314 cases. One objective was to analyze the clinical and pathologic features of 340 cases of PTCL, not otherwise specified. The median age of the patients was 60 years, and the majority (69%) presented with advanced stage disease. Most patients (87%) presented with nodal disease, but extranodal disease was present in 62%. The 5-year overall survival was 32%, and the 5-year failure-free survival was only 20%. The majority of patients (80%) were treated with combination chemotherapy that included an anthracycline, but there was no survival advantage. The International Prognostic Index (IPI) was predictive of both overall survival and failure-free survival (P < .001). Multivariate analysis of clinical and pathologic prognostic factors, respectively, when controlling for the IPI, identified bulky disease (≥ 10 cm), thrombocytopenia (< 150 × 10(9)/L), and a high number of transformed tumor cells (> 70%) as adverse predictors of survival, but only the latter was significant in final analysis. Thus, the IPI and a single pathologic feature could be used to stratify patients with PTCL-not otherwise specified for novel and risk-adapted therapies.

[1]  Christine F. Wogan,et al.  Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Imbert,et al.  Peripheral T‐cell lymphoma gene expression profiling and potential therapeutic exploitations , 2010, British journal of haematology.

[3]  O. O’Connor,et al.  Targeted treatment and new agents in peripheral T-cell lymphoma , 2010, International journal of hematology.

[4]  F. Foss Enhancing existing approaches to peripheral T-cell lymphoma. , 2010, Seminars in hematology.

[5]  Enzo Medico,et al.  Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Chan,et al.  Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. , 2010, Blood.

[7]  P. Gaulard,et al.  Molecular classification of T-cell lymphomas. , 2009, Critical reviews in oncology/hematology.

[8]  T. Miller,et al.  Localized large cell lymphoma: is there any need for radiation therapy? , 2009, Current opinion in oncology.

[9]  B. Martínez-Delgado,et al.  Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. , 2009, Critical reviews in oncology/hematology.

[10]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Nakamine,et al.  Clinico‐pathologic features and outcome of Japanese patients with peripheral T‐cell lymphomas , 2008, Hematological oncology.

[12]  Christopher R Flowers,et al.  Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States , 2008, Leukemia & lymphoma.

[13]  Keunchil Park,et al.  Clinical features and prognostic factors of patients with “peripheral T cell lymphoma, unspecified” , 2008, Annals of Hematology.

[14]  K. Petráková,et al.  Peripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry. , 2007, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[15]  P. Gaulard,et al.  Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. , 2006, Blood.

[16]  S. Pileri,et al.  Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[18]  Y. Kagami,et al.  Clinicopathologic and Prognostic Significance of Cytotoxic Molecule Expression in Nodal Peripheral T-Cell Lymphoma, Unspecified , 2005, The American journal of surgical pathology.

[19]  N. Schmitz,et al.  The International Prognostic Index determines the outcome of patients with nodal mature T‐cell lymphomas , 2005, British journal of haematology.

[20]  Y. Kwong,et al.  Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Y. Yamashita,et al.  Clinicopathological features and prognostic factors of Japanese patients with "peripheral T-cell lymphoma, unspecified" diagnosed according to the WHO classification. , 2004, Leukemia research.

[22]  R. Gascoyne,et al.  Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  H. Müller-Hermelink,et al.  Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert’s) variant are often derived from CD8+ cytotoxic T-cells , 2004, Virchows Archiv.

[24]  E. Iannitto,et al.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.

[25]  C. Gasparetto High-Dose Therapy and Stem Cell Transplantation , 2004 .

[26]  D. Morgan,et al.  Peripheral T-cell Lymphomas: Clinical Features and Prognostic Factors of 92 Cases Defined by the Revised European American Lymphoma Classification , 2003, Leukemia & lymphoma.

[27]  R. Pickering,et al.  A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma , 2002, Annals of Hematology.

[28]  B. Nathwani,et al.  Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Keunchil Park,et al.  Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. , 2002, European journal of cancer.

[30]  A. López-Guillermo,et al.  Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  D. Weisenburger,et al.  Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  P. Gaulard,et al.  Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.

[33]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[34]  S. Pileri,et al.  Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[36]  M. Engelhard,et al.  Lymphoepithelioid cell lymphoma (Lennert's lymphoma): clinical features derived from analysis of 108 cases , 1993, British journal of haematology.

[37]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.

[38]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[39]  D.,et al.  Regression Models and Life-Tables , 2022 .